欢迎来到天天文库
浏览记录
ID:55658163
大小:228.19 KB
页数:3页
时间:2020-05-23
《聚乙二醇干扰素α-2a联合乙肝疫苗治疗慢性乙型肝炎疗效观察.pdf》由会员上传分享,免费在线阅读,更多相关内容在应用文档-天天文库。
1、·34·实用肝脏病杂志2014年1月第l7卷第1期JPraeHepatol,Jan.20..7No.1·病毒性肝炎·聚乙二醇干扰素仪一2a联合乙肝疫苗治疗慢性乙型肝炎疗效观察陆建国【摘要】目的探讨聚乙二醇干扰素d一2a(PEG—IFN0【一2a)联合乙肝疫苗治疗慢性乙型肝炎(CHB)的临床疗效及安全性。方法随机将172例CHB患者分为观察组和对照组,每组86例。对照组应用PEG—IFNot一2a治疗,观察组应用PEG—IFNot一2a联合乙肝疫苗治疗。比较两组在治疗6m、12m和随访6m时HBVD
2、NA阴转率、HBeAg阴转率和ALT复常率。结果在治疗12m和随访6m时,观察组HBVDNA阴转率、HBeAg阴转率和ALT复常率分别为81.4%、53.5%和82.6%,和93.0%、64.0%和95.3%,均显著高于对照组水平(67.4%、38.7%和68.6%,和75.6%、46.5%和77.9%,P3、、(36.5±11-3)U/L和(43.2±15.7)U/L,均显著低于对照组(116.4±58.6)U/L和(105.34-52.8)U/L、(50.6±26_2)U/L和(59.5±25.4)U/L、(46.0±24.4)U/L和(52.6±23.9)U/L,P<0.05。结论PEG—IFN一2a联合乙肝疫苗治疗CHB可有效地提高干扰素的临床疗效。【关键词】慢性乙型肝炎;聚乙二醇干扰素0【一2a;乙肝疫苗;疗效DOI:10.3969~.issn.1672-5069.2014.01.010Com4、binationtherapyofpegylatedinterferonalpha。2aandhepatitisBvaccineintreatmentofpatientswithchronichepatitisBLuJianguo.TheFirstAffiliatedHospita1.LiuzhouUniversityofScienceandTechnalo—gY,Liuzhou545002,GuangxiZhuangAutonomott8Region,China【Abstract】0bjecti5、veToinvestigatetheeficacyandsafetyofcombinationtherapyofpegylatedinterferon仅一2a(PEG—IFN一2a)andhepatitisBvaccineintreatmentofpatientswithchronichepatitisB(CHB).MethodsOnehundredandseventy—twopatientswithCHBinourhospitalfromOctober,2008toOctober,2012wer6、erecruitedandrandomlydividedintoobservationgroup(PEG—IFNa-2aplushepatitisBvaccine)andcontrolgroup(PEG—IF—N一2aalone,86casesineachgroup);ThenegativeconversionratesofselllmHBVDNAandHBeAg,normaliza-tionratesofAlJTandadvemeeventsat6and12monthsaftertreatmen7、tandattheendof6-month~llowed-upbetweenthetwogroupswerecompared.ResultsThenegativeconversionratesofHBVDNAandHBeAg,andtheAIJTnormalizationratesinobservationgroupat6and12monthsaftertreatmentand6months~llowed—upwere81.4%,53.5%,82.6%and93.0%,64.0%,95.3%,re8、spectively,allofwhichweresignificantlyhigherthanthoseofcorrespondingparametersincontrolgroup(67.4%,38.7%,68.6%and75.6%,46.5%,77.9%,respectively,P<0.05);ThescramAandASTlevelsat6and12monthsaftertreatmentandat6-month~llowed—upinobservationgroupwe
3、、(36.5±11-3)U/L和(43.2±15.7)U/L,均显著低于对照组(116.4±58.6)U/L和(105.34-52.8)U/L、(50.6±26_2)U/L和(59.5±25.4)U/L、(46.0±24.4)U/L和(52.6±23.9)U/L,P<0.05。结论PEG—IFN一2a联合乙肝疫苗治疗CHB可有效地提高干扰素的临床疗效。【关键词】慢性乙型肝炎;聚乙二醇干扰素0【一2a;乙肝疫苗;疗效DOI:10.3969~.issn.1672-5069.2014.01.010Com
4、binationtherapyofpegylatedinterferonalpha。2aandhepatitisBvaccineintreatmentofpatientswithchronichepatitisBLuJianguo.TheFirstAffiliatedHospita1.LiuzhouUniversityofScienceandTechnalo—gY,Liuzhou545002,GuangxiZhuangAutonomott8Region,China【Abstract】0bjecti
5、veToinvestigatetheeficacyandsafetyofcombinationtherapyofpegylatedinterferon仅一2a(PEG—IFN一2a)andhepatitisBvaccineintreatmentofpatientswithchronichepatitisB(CHB).MethodsOnehundredandseventy—twopatientswithCHBinourhospitalfromOctober,2008toOctober,2012wer
6、erecruitedandrandomlydividedintoobservationgroup(PEG—IFNa-2aplushepatitisBvaccine)andcontrolgroup(PEG—IF—N一2aalone,86casesineachgroup);ThenegativeconversionratesofselllmHBVDNAandHBeAg,normaliza-tionratesofAlJTandadvemeeventsat6and12monthsaftertreatmen
7、tandattheendof6-month~llowed-upbetweenthetwogroupswerecompared.ResultsThenegativeconversionratesofHBVDNAandHBeAg,andtheAIJTnormalizationratesinobservationgroupat6and12monthsaftertreatmentand6months~llowed—upwere81.4%,53.5%,82.6%and93.0%,64.0%,95.3%,re
8、spectively,allofwhichweresignificantlyhigherthanthoseofcorrespondingparametersincontrolgroup(67.4%,38.7%,68.6%and75.6%,46.5%,77.9%,respectively,P<0.05);ThescramAandASTlevelsat6and12monthsaftertreatmentandat6-month~llowed—upinobservationgroupwe
此文档下载收益归作者所有